Biotech

China’s flagship project, the National Biobank, has grown into one of the world’s largest since launching in Shenzhen in 2016 and Beijing is pushing to make it the biggest.

Global Enterprise

China races to build record biobank to rival US drugs research

Beijing has equally begun to protect its own nascent databases, passing a biosecurity law in 2020

Alps Group's Dr Tham Seng Kong says: "The challenge is no longer about developing technology, but ensuring that it can be used by the mass market. The problem is, most people cannot afford it."

Asean Business

Less than six months after Nasdaq debut, Malaysia’s Alps Group pivots to bridge biotech access gap

It is expanding into insurance and education to rebuild valuation and put advanced treatments within reach for more people

Gilead will pay US$3.15 billion upfront in cash, and up to US$1.85 billion more if certain milestones are met.

Companies & Markets

Gilead to buy cancer biotech Tubulis in US$5 billion deal

After the deal closes, Tubulis will become a research arm within Gilead

Haim Brosh, executive director and CEO at The Trendlines Group, is leading a strategic pivot aimed at streamlining operations.

Companies & Markets

TOPLINE

Now back in the black, SGX-listed Trendlines doubles down on core bets

The group is concentrating on assets in its strongest portfolio companies, says CEO Haim Brosh

The transactions – the majority of which occurred in the second half of 2025 – relate to prepayments in connection with new projects.

Companies & Markets

US$14.8 million in prepayments to vendors behind Mirxes’ missed 2025 results deadline; independent probe set up

The investigation committee will oversee a review of 14 transactions and ‘associated subsequent events’

For the five trading sessions spanning Mar 13 to 19, institutions were net buyers of Singapore stocks.

Companies & Markets

INSIDE INSIGHTS

Insider and institutional positioning for the week

[SINGAPORE] For the five trading sessions spanning Mar 13 to 19, institutions were net buyers of Singapore stocks, with net institutional inflow of S$365 million. This took the accumulated net inflow ...

Across Asia, governments have made biotech a strategic priority, enacting policy and ecosystem changes that reduce friction throughout the innovation life cycle.

Opinion & Features

Asia’s biotech moment: From regional strength to global impact

Policy reform, new models and cross-border platforms make the region a key driver of biopharma innovation

The CL1 units use neurons that have been converted from human blood cells.

Startups

Human brain cells run new data centres in Singapore, Melbourne

AI is driving a surge in electricity demand, forcing governments and technology companies to search for more efficient computing systems

Cytek CEO Jiang Wenbin (third from right) says the company will continue to focus on expanding its facility and investments in Singapore to drive its Asia-Pacific growth.

Companies & Markets

Nasdaq-listed biotech company Cytek boosts Singapore facility with US$3 million investment

The firm aims to use the site to spearhead growth in Asia-Pacific

Ricky Lin, founder and CEO of Life3 Biotech, says the facility is intended to reflect Life3’s broader positioning beyond production, as well as its identity as a “social enterprise at heart”.

SGSME

AI-powered microalgae hub to anchor Life3 Biotech’s position in sustainable proteins

Facility slated for completion in the fourth quarter of 2026 will house AI-driven bioreactors and a new visitor centre

Latest T-bills Treasury Bills Results & Interest News Latest SSB Singapore Savings Bonds News Latest COE Certificate of Entitlement News

Latest Johor-Singapore SEZ News Latest BTO Build To Order & Sales of Balance News Latest STI Straits Times Index News Latest SGX Dividends, Share Price News Latest Bonds Market News Latest Singapore Stocks To Buy News Latest Singapore Economy News